Proposed acquisition adds Nimble's lead asset, an investigational oral peptide IL23R inhibitor in preclinical development for psoriasis, and a pipeline of other novel oral peptide assets across autoimmune diseases where significant unmet needs remainAcquisition also allows AbbVie to utilize Nimble's proprietary peptide synthesis platform to enable the discovery and optimization of oral peptide therapeuticsNORTH CHICAGO, Ill.

拟议的收购增加了Nimble的领先资产，这是一种用于牛皮癣临床前开发的研究性口服肽IL23R抑制剂，以及跨越自身免疫性疾病的其他新型口服肽资产的管道，其中大量未满足的需求仍然存在，这也使AbbVie能够利用Nimble专有的肽合成平台来发现和优化口服肽治疗剂伊利诺伊州芝加哥。

and MADISON, Wis., Dec. 13, 2024 /PRNewswire/ -- AbbVie (NYSE: ABBV) and Nimble Therapeutics today announced a definitive agreement under which AbbVie will acquire Nimble, including its lead asset, an investigational oral peptide IL23R inhibitor in preclinical development for the treatment of psoriasis and a pipeline of other novel oral peptide candidates with potential across several autoimmune diseases.

和威斯康星州麦迪逊，2024年12月13日/PRNewswire/--AbbVie（纽约证券交易所：ABBV）和Nimble Therapeutics今天宣布了一项最终协议，根据该协议，AbbVie将收购Nimble，包括其主要资产，一种用于治疗牛皮癣的临床前开发的研究性口服肽IL23R抑制剂，以及一系列其他可能跨越多种自身免疫性疾病的新型口服肽候选药物。

Additionally, AbbVie will acquire Nimble's peptide synthesis, screening, and optimization platform, which uses proprietary technology to help drive rapid discovery and optimization of peptide candidates for a range of targets..

此外，AbbVie将收购Nimble的肽合成，筛选和优化平台，该平台使用专有技术帮助快速发现和优化一系列目标的肽候选物。。

'The addition of Nimble's pipeline to AbbVie's existing pipeline, combined with our deep clinical and translational expertise in immunology, represents an important growth opportunity,' said Jonathon Sedgwick, Ph.D., senior vice president and global head of discovery research, AbbVie. 'Together, AbbVie and Nimble have the potential to help address the significant unmet medical need for people living with autoimmune diseases.'.

AbbVie高级副总裁兼发现研究全球负责人乔纳森·塞奇威克（JonathonSedgwick）博士说：“在AbbVie现有渠道的基础上增加了Nimble的渠道，再加上我们在免疫学方面深厚的临床和转化专业知识，这是一个重要的增长机会。”AbbVie和Nimble共同有可能帮助解决自身免疫性疾病患者的重大未满足医疗需求。”。

'Nimble Therapeutics is committed to transforming the discovery of oral peptide-based medicines. With AbbVie's world-class expertise in developing and commercializing medicines on a global scale, Nimble's novel oral therapies will be well-positioned to reach more people living with autoimmune diseases,' said Jigar Patel, Ph.D., founder and chief executive officer, Nimble Therapeutics.

“Nimble Therapeutics致力于改变口服肽类药物的发现。“凭借艾伯维在全球范围内开发和商业化药物方面的世界级专业知识，Nimble的新型口服疗法将有助于接触更多患有自身免疫性疾病的人，”Nimble Therapeutics创始人兼首席执行官吉加·帕特尔（JigarPatel）博士说。

'The talented, passionate and dedicated team at Nimble has made great progress over the past few years and we are pleased that AbbVie has recognized the tremendous potential of our proprietary platform and emerging immunology pipeline.'.

“在过去几年中，Nimble的才华横溢，充满激情和敬业精神的团队取得了巨大进步，我们很高兴AbbVie认识到我们专有平台和新兴免疫学管道的巨大潜力。”。

Nimble's preclinical-stage IL23R inhibitor is an investigational oral therapy for the treatment of psoriasis and inflammatory bowel disease (IBD). IL23R is a clinically validated therapeutic target in certain autoimmune diseases and a major contributing factor to psoriasis and IBD pathogenesis and progression through increased inflammation and amplified immune responses..

Nimble的临床前阶段IL23R抑制剂是一种用于治疗牛皮癣和炎症性肠病（IBD）的研究性口服疗法。IL23R是某些自身免疫性疾病的临床验证治疗靶点，是银屑病和IBD发病机制的主要因素，并通过增加炎症和增强免疫反应而进展。。

Under the terms of the agreement, AbbVie will make a cash payment of $200 million at closing to acquire Nimble, subject to certain customary adjustments, in addition to certain interim funding payments. Nimble's shareholders remain eligible for a potential payment, subject to the achievement of a development milestone.

根据协议条款，AbbVie将在交割时支付2亿美元的现金，以收购Nimble，除某些临时资金支付外，还将进行某些常规调整。Nimble的股东仍然有资格获得潜在的付款，这取决于发展里程碑的实现。

The transaction is subject to the satisfaction of customary closing conditions, including the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act..

该交易须符合惯例成交条件，包括哈特·斯科特·罗迪诺反托拉斯改进法案规定的适用等待期。。

Nimble is backed by founding investors Telegraph Hill Partners and Roche Ventures.

Nimble得到了创始投资者Telegraph Hill Partners和Roche Ventures的支持。

About AbbVie

关于AbbVie

AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. AbbVie strives to have a remarkable impact on people's lives across several key therapeutic areas – immunology, oncology, neuroscience, and eye care – and products and services in AbbVie's Allergan Aesthetics portfolio.

AbbVie的使命是发现并提供创新药物和解决方案，以解决当今严重的健康问题，并应对未来的医疗挑战。AbbVie致力于在几个关键治疗领域（免疫学、肿瘤学、神经科学和眼部护理）以及AbbVie Allergan美学组合中的产品和服务中对人们的生活产生显着影响。

For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on LinkedIn, Facebook, Instagram, X (formerly Twitter), and YouTube. .

有关AbbVie的更多信息，请访问www.AbbVie.com。在LinkedIn、Facebook、Instagram、X（以前的Twitter）和YouTube上关注@AbbVie。。

About Nimble Therapeutics

关于敏捷疗法

Nimble is a biotechnology company dedicated to delivering on the promise of oral peptide therapeutics. Leveraging a paradigm-shifting peptide drug discovery and development engine, Nimble is advancing its internal pipeline and continues to support several partnered programs. The Nimble platform combines massively parallel solid-phase synthesis, unrivaled chemical and structural diversity, sophisticated assays, and powerful machine learning and computational methods.

Nimble是一家生物技术公司，致力于实现口服肽疗法的承诺。。灵活的平台结合了大规模并行固相合成，无与伦比的化学和结构多样性，复杂的测定以及强大的机器学习和计算方法。

Nimble is located in Madison, WI and Philadelphia, PA..

Nimble位于威斯康星州麦迪逊和宾夕法尼亚州费城。。

No Offer or Solicitation

无要约或招揽

This press release is for information purposes only and is not intended to and does not constitute, or form part of, an offer, invitation or the solicitation of an offer or invitation to purchase, otherwise acquire, subscribe for, sell or otherwise dispose of any securities, or the solicitation of any vote or approval in any jurisdiction, pursuant to the proposed transaction or otherwise, nor shall there be any sale, issuance or transfer of securities in any jurisdiction in contravention of applicable law..

本新闻稿仅供参考，不打算也不构成根据拟议交易或其他方式在任何司法管辖区内要约、邀请或邀请购买、以其他方式获取、认购、出售或以其他方式处置任何证券，或邀请任何投票或批准，也不构成或构成要约、邀请或邀请的一部分，也不违反适用法律在任何司法管辖区内出售、发行或转让任何证券。。

Forward-Looking Statements

前瞻性声明

Some statements in this news release are, or may be considered, forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. The words 'believe,' 'expect,' 'anticipate,' 'project' and similar expressions and uses of future or conditional verbs, generally identify forward-looking statements.

就1995年《私人证券诉讼改革法案》而言，本新闻稿中的一些声明是或可能被视为前瞻性声明。单词“相信”、“期望”、“预期”、“项目”以及类似的将来动词或条件动词的表达和用法通常表示前瞻性陈述。

AbbVie cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those expressed or implied in the forward-looking statements. Such risks and uncertainties include, but are not limited to, challenges to intellectual property, competition from other products, difficulties inherent in the research and development process, adverse litigation or government action, and changes to laws and regulations applicable to our industry.

AbbVie警告称，这些前瞻性声明存在风险和不确定性，可能导致实际结果与前瞻性声明中明示或暗示的结果存在重大差异。此类风险和不确定性包括但不限于知识产权的挑战、其他产品的竞争、研发过程中固有的困难、不利的诉讼或政府行为以及适用于本行业的法律法规的变化。

Additional information about the economic, competitive, governmental, technological and other factors that may affect AbbVie's operations is set forth in Item 1A, 'Risk Factors,' of AbbVie's 2023 Annual Report on Form 10-K, which has been filed with the Securities and Exchange Commission, as updated by its subsequent Quarterly Reports on Form 10-Q.

有关可能影响艾伯维运营的经济、竞争、政府、技术和其他因素的其他信息，请参见艾伯维2023年年度报告表10-K第1A项“风险因素”，该报告已提交给美国证券交易委员会，并由其随后的10-Q表季度报告更新。

Forward looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward looking statements, and AbbVie undertakes no obligation, and specifically declines, to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law. .

前瞻性声明仅在做出之日起生效。警告读者不要过度依赖前瞻性声明，除非法律要求，否则AbbVie没有义务（特别拒绝）公开发布因后续事件或发展而对前瞻性声明进行的任何修订。。

SOURCE AbbVie

来源AbbVie